Today, we will be providing an overview of the latest developments in the field of Infectious Diseases up to April 2024. This includes new medications, new guidelines, and noteworthy research and journal articles that have been published in the first four months of the year.

Recent Infectious Diseases-Related Clinical Guidelines

  1. Respiratory Isolation and Restrictions to Reduce Transmission of Pulmonary Tuberculosis in Community Settings (NTCA) (April 18, 2024)
  1. Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection (WHO) (March 29, 2024)
  1. 18F-FDG PET/CT and Radiolabeled Leukocyte SPECT/CT Imaging for the Evaluation of Cardiovascular Infection in the Multimodality Context: ASNC Imaging Indications ASNC I2 Series (Multiple Organizations (March 11, 2024)
  1. Use of p16/Ki67 Dual Stain for Management of Individuals Testing Positive for Human Papillomavirus (ASCCP) (March 6, 2024)
  1. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases (IDSA) (March 5, 2024)
  1. Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases (AGA) (February 21, 2024)
  1. Bacterial Keratitis (AAO) (February 11, 2024)
  1. Diagnosis and Management of Cryptococcosis (ISHAM/ECMM) (February 9, 2024)
  1. COVID-19 Guideline Part 4: Serologic Testing (IDSA) (February 9, 2024)
  1. Laboratory Recommendations for Syphilis Testing (CDC) (February 8, 2024)
  1. Clinical Management of Diphtheria (WHO) (February 2, 2024)
  1. Influenza in Pregnancy: Prevention and Treatment (ACOG) (February 1, 2024)
  1. Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States (DHHS) (January 31, 2024)
  1. Recommended Childhood and Adolescent Immunization Schedule: United States, 2024 (CDC) (January 29, 2024)
  1. Use of Corticosteroids in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia (SCCM) (January 19, 2024)
  1. Recommended Adult Immunization Schedule: United States, 2024 (CDC) (January 12, 2024)

Recent Infectious Disease-Related FDA Medication Approvals

April 24, 2024
Pivmecillinam (Pivya)
Utility Therapeutics
For treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus

April 8, 2024
Dolutegravir/lamivudine (Dovato)
ViiV
Expanded indication
For the treatment of HIV-1 infection in adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato

April 3, 2024
Ceftobiprole medocaril (Zevtera)
Basilea
For adults with acute bacterial skin and skin structure infections (ABSSSI) and adults with staphylococcus aureus bacteremia (SAB), a bloodstream infection that can be fatal. It also can be used on patients 3 months and older to combat community-acquired bacterial pneumonia (CABP)

March 28, 2024
Tenofovir alafenamide (Vemlidy)
Gilead
Expanded indication
For chronic hepatitis B virus (HBV) infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease

March 19, 2024
Rilpivirine (Edurant PED)
Janssen
For treatment of HIV-1 in combination with other antiretroviral therapies (ARVs) in treatment-naïve children (with HIV-1 RNA <100,000 copies/mL) at least 2 years of age and weighing at least 14 kg and less than 25 kg

February 27, 2024
Cefepime/enmetazobactam (Exblifep)
Allecra Therapeutics
For treatment for complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older

February 26, 2024
Bictegravir/emtricitabine/tenofovir/alafenamide (Biktarvy)
Gilead
Expanded indication
For treatment of people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance

Looking ahead to the next third of the year, through August 2024 We expect a number of new guidelines from the IDSA to publish sometime before the end of June. This includes:

  • Intra-Abdominal Infections Part 1 (IDSA)
  • Community-Acquired Pneumonia in Adult Update (IDSA/ATS)
  • Drug-Susceptible and Drug-Resistant Tuberculosis UPDATE (IDSA/ATS/ERS/CDC)
  • Treatment of Uncomplicated Urinary Tract Infections Part 1 (IDSA)
  • Ongoing updates to COVID-19 Guidance (IDSA)

This concludes our Guidelines Rundown for Infectious Diseases through the first third of 2024.  Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2024 Guideline Central, All rights reserved.